UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010975
Receipt number R000012845
Scientific Title Effects of 3% diquafosol sodium ophthalmic solution on visual function in patient with dry eye wearing contact lens.
Date of disclosure of the study information 2013/06/30
Last modified on 2013/06/15 13:44:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of 3% diquafosol sodium ophthalmic solution on visual function in patient with dry eye wearing contact lens.

Acronym

Effects of 3% diquafosol sodium ophthalmic solution on visual function in patient with dry eye wearing contact lens.

Scientific Title

Effects of 3% diquafosol sodium ophthalmic solution on visual function in patient with dry eye wearing contact lens.

Scientific Title:Acronym

Effects of 3% diquafosol sodium ophthalmic solution on visual function in patient with dry eye wearing contact lens.

Region

Japan


Condition

Condition

dry eye

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

o investigate the efficacy of 4 weeks administration of 3% diquafosol sodium ophthalmic solution on visual function in patients with dry eye who wear contact lenses routinely and complain decreased visual performance. TO investigate the change of subjective and objective symptoms associated with dry eye.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Change of visual function
Change of subjective symptoms

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Instillation of 3% diquafosol sodium ophthalmic solution, 6 times daily for 4 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

At time of informed consent
1) 20 years old and older.
2) Wearing contact lenses routinely.
At time of starting administration
1) Diagnosed patients with dry eye or dry eye suspects based on dry eye diagnostic criteria (2006).
2) Patients with wearing 1 day acuvue moist; routinely for 1week or longer and complaining decreased visual performance.

Key exclusion criteria

1) History of administered diquafosol sodium ophthalmic solution and/or rebamipide ophthalmic solution within one week before start of study.
2) Anatomically and/or functionally abnormal eyelid. (ex. eyelid closure abnormality)
3) History of ophthalmic surgery (including laser therapy) within 3 months before start of study.
4) History of occluding punctum. (ex. punctal plug or a punctal closing surgery)
5) Presence of a hypersensitivity to drugs scheduled to be used. (ex. diquafosol sodium, fluorescein, oxybuprocaine hydrochloride)
6) Presence of any other medical concern that may affect the accurate efficacy assessment or ensuring safety.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ikuko Toda

Organization

Minamiaoyama Eye Clinic Tokyo

Division name

Director

Zip code


Address

3-3-11 Kita-aoyama Minato-ku Tokyo

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Minamiaoyama Eye Clinic Tokyo

Division name

Director

Zip code


Address


TEL

03-5772-1440

Homepage URL


Email



Sponsor or person

Institute

Minamiaoyama Eye Clinic Tokyo

Institute

Department

Personal name



Funding Source

Organization

Santen Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 06 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2013 Year 04 Month 28 Day

Date of IRB


Anticipated trial start date

2013 Year 06 Month 20 Day

Last follow-up date

2013 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 06 Month 15 Day

Last modified on

2013 Year 06 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012845


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name